<DOC>
	<DOC>NCT01332981</DOC>
	<brief_summary>This is an observational follow-up study on the efficacy of 1st-line treatment with Herceptin (trastuzumab) in patients with metastatic breast cancer 7 years after initiation of treatment.</brief_summary>
	<brief_title>An Observational Follow-up Study of 1st-Line Treatment With Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer (Post-HERMINE)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female patient, &gt;/= 18 years of age Metastatic breast cancer 1stline treatment with Herceptin initiated in 2002 Included in pharmacoepidemiologic HERMINE study Patient died before scheduled followup visit (March 2005)</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>